T-lymphocyte costimulatory pathways

T-lymphocyte costimulatory pathways represent a critical set of secondary signals, often referred to as 'Signal 2', required for the full activation, proliferation, and survival of T cells following antigen recognition by the T-cell receptor (TCR) [1.3.1, 1.3.2]. These pathways are primarily mediated by two major protein families: the immunoglobulin (Ig) superfamily, such as CD28 and ICOS, and the tumor necrosis factor receptor (TNFR) superfamily, including OX40 and 4-1BB [1.4.1]. In a healthy immune system, these signals ensure robust responses against pathogens while maintaining self-tolerance through a balance of stimulatory and inhibitory (checkpoint) signals [1.2.3, 1.4.4]. Dysregulation of these pathways is central to the pathogenesis of various diseases; overactivity can lead to autoimmune disorders like rheumatoid arthritis and transplant rejection, while suppression or evasion of these signals is a hallmark of cancer [1.1.3, 1.3.2]. Therapeutically, these pathways are targeted using either antagonists, such as the CTLA-4-Ig fusion proteins abatacept and belatacept, to induce immune tolerance, or agonists and checkpoint inhibitors, like ipilimumab and nivolumab, to restore anti-tumor immunity [1.1.1, 1.1.2]. These interventions aim to modulate the immune response by either amplifying or dampening the costimulatory signals necessary for T-cell effector function and memory formation [1.2.2, 1.4.4].

Other names

T-cell costimulationSignal 2Co-stimulatory signalingT-cell co-signalingCostimulatory molecules

Modulation of secondary signals required for T-cell activation, either by blocking costimulatory interactions to induce tolerance or by agonizing them to enhance anti-tumor immunity.